BMRN
54.71 USD
-0.76%
Today
-0.18%
1D
Market is open
Sun
Closed
Mon
3:00 AM ~ 12:00 PM
Tue
12:00 AM ~ 12:00 PM
Wed
12:00 AM ~ 12:00 PM
Thu
12:00 AM ~ 12:00 PM
Fri
12:00 AM ~ 12:00 PM
Sat
Closed
Information
Name
BioMarin Pharmaceutical Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0190%
Overnight Fees Sell
0.0024%
Market Cap
11.07B
Avg Daily Volume
1.96M
52 Week High
70.98 USD
52 Week Low
49.26 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01900% | $(0.190) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Top News
BioMarin
-0.18%
BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?
finance.yahoo.com
1h ago
BioMarin
-0.18%
BioMarin Q3 financial results to see IPR&D expense impact of $283M
tradingview.com
1d ago
BioMarin
-0.18%
BioMarin Pharmaceutical Inc. (BMRN) Appoints Cara Bauer as Chief People Officer
tradingview.com
2d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
